Germany, Spain, and Italy lead in registered rheumatoid arthritis stem-cell trials, with university rheumatology departments collaborating with cell-therapy centres. Poland and Czech Republic also conduct active research with lower cost structures. Austria has several registered trials within university hospitals. France maintains selected protocols at teaching hospitals. United States capacity is fragmented; the NIH database lists fewer US-based RA-specific MSC trials than European alternatives. Selection should prioritise published safety data, trial registration, and institutional credentials in rheumatology, not marketing claims.
Rheumatoid arthritis stem-cell treatment costs typically range €3,500–6,500 per infusion, depending on cell source, expansion scale, and delivery route. Intra-articular injection into one or few joints is less expensive than systemic administration. Placental MSCs are favoured for cost-efficiency and immunogenicity profile relative to other sources. Disease duration and number of affected joints may influence whether monotherapy or repeat infusions are proposed. European programmes in Italy, Germany, and Spain generally charge at the lower end; private boutique clinics may exceed €7,000. Some trial sites offer treatments at reduced cost to enrolled participants.
Am I a candidate? → · Rheumatoid Arthritis: full overview → · Rheumatoid Arthritis cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite